These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 12894128)
1. The design of clinical trials in psoriasis: lessons for clinical practice. Feldman SR J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S62-5. PubMed ID: 12894128 [TBL] [Abstract][Full Text] [Related]
2. Reconsideration of 2008 decision: Food and Drug Administration approval of etanercept for systemic treatment of moderate to severe pediatric psoriasis. Gatti J; Lindstrom JA; Beitz J Pediatr Dermatol; 2018 Sep; 35(5):688-689. PubMed ID: 30066378 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of the fragility of pivotal trials used to support US Food and Drug Administration approval for plaque psoriasis. Shalhout SZ; Bloom R; Drake L; Miller DM J Am Acad Dermatol; 2021 Feb; 84(2):354-360. PubMed ID: 32320767 [TBL] [Abstract][Full Text] [Related]
4. How are drugs approved? Part 1: the evolution of the Food and Drug Administration. Howland RH J Psychosoc Nurs Ment Health Serv; 2008 Jan; 46(1):15-9. PubMed ID: 18251347 [TBL] [Abstract][Full Text] [Related]
5. The seamless approach to drug development in oncology. Pazdur R Clin Adv Hematol Oncol; 2016 Dec; 14(12):958-959. PubMed ID: 28212356 [No Abstract] [Full Text] [Related]
6. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies. Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616 [TBL] [Abstract][Full Text] [Related]
7. How are drugs approved? Part 3. The stages of drug development. Howland RH J Psychosoc Nurs Ment Health Serv; 2008 Mar; 46(3):17-20. PubMed ID: 18416270 [TBL] [Abstract][Full Text] [Related]
8. Safety surveillance in drug development: understanding the process and its implications for nephrology nursing. Browar S Nephrol Nurs J; 2002 Apr; 29(2):143-50. PubMed ID: 11997949 [TBL] [Abstract][Full Text] [Related]
9. Expanded Access to Investigational Drugs: What Physicians and the Public Need to Know about FDA and Corporate Processes. Finkelstein PE AMA J Ethics; 2015 Dec; 17(12):1142-6. PubMed ID: 26698587 [No Abstract] [Full Text] [Related]
10. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective. Khin NA; Yang P; Hung HM; Maung-U K; Chen YF; Meeker-O'Connell A; Okwesili P; Yasuda SU; Ball LK; Huang SM; O'Neill RT; Temple R Clin Pharmacol Ther; 2013 Aug; 94(2):230-42. PubMed ID: 23588316 [TBL] [Abstract][Full Text] [Related]
11. Changes at FDA may speed drug approval process and increase off-label use. Reh M J Natl Cancer Inst; 1998 Jun; 90(11):805-7. PubMed ID: 9625166 [No Abstract] [Full Text] [Related]
12. A critical tipping point. Zuckerman MB US News World Rep; 2002 Apr; 132(13):72. PubMed ID: 11993366 [No Abstract] [Full Text] [Related]
13. Trials and error. Jacobs T Nat Biotechnol; 2005 Dec; 23(12):1481. PubMed ID: 16333284 [No Abstract] [Full Text] [Related]
14. FDA and EMEA pool scientific advice. Katsnelson A Nat Biotechnol; 2004 Dec; 22(12):1490-1. PubMed ID: 15583642 [No Abstract] [Full Text] [Related]
15. The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology. McKee AE; Farrell AT; Pazdur R; Woodcock J Oncologist; 2010; 15 Suppl 1():13-8. PubMed ID: 20237212 [TBL] [Abstract][Full Text] [Related]
16. The special treatment. Osborne R Nat Biotechnol; 2008 May; 26(5):487-9. PubMed ID: 18464770 [No Abstract] [Full Text] [Related]